PYRIDOSTIGMINE BROMIDE tablet

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

Pyridostigmine Bromide (UNII: KVI301NA53) (Pyridostigmine - UNII:19QM69HH21)

Disponível em:

Oceanside Pharmaceuticals

DCI (Denominação Comum Internacional):

Pyridostigmine Bromide

Composição:

Pyridostigmine Bromide 60 mg

Via de administração:

ORAL

Tipo de prescrição:

PRESCRIPTION DRUG

Indicações terapêuticas:

Pyridostigmine Bromide Tablets are contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

Resumo do produto:

Pyridostigmine Bromide Tablets, USP are available containing 60 mg of pyridostigmine bromide each in bottles of 100 (NDC 68682-302-10). Each tablet is cross-scored on one side and engraved "OCEANSIDE 302" on the other side. Store Pyridostigmine Bromide Tablets at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Keep Pyridostigmine Bromide Tablets in a dry place with the silica gel enclosed.

Status de autorização:

New Drug Application Authorized Generic

Características técnicas

PYRIDOSTIGMINE BROMIDE- PYRIDOSTIGMINE BROMIDE TABLET
OCEANSIDE PHARMACEUTICALS
----------
PYRIDOSTIGMINE BROMIDE TABLETS, USP
60 MG
RX ONLY
DESCRIPTION
Pyridostigmine Bromide Tablets, USP is an orally active cholinesterase
inhibitor. Chemically,
pyridostigmine bromide is 3-hydroxy-1-methylpyridinium bromide
dimethylcarbamate. Its structural
formula is:
Pyridostigmine bromide is available as tablets containing 60 mg
pyridostigmine bromide; each tablet
also contains lactose, silicon dioxide and stearic acid.
ACTIONS:
Pyridostigmine bromide inhibits the destruction of acetylcholine by
cholinesterase and thereby permits
freer transmission of nerve impulses across the neuromuscular
junction. Pyridostigmine is an analog of
neostigmine (Prostigmin), but differs from it in certain clinically
significant respects; for example,
pyridostigmine is characterized by a longer duration of action and
fewer gastrointestinal side effects.
INDICATION
Pyridostigmine Bromide Tablets are useful in the treatment of
myasthenia gravis.
CONTRAINDICATIONS
Pyridostigmine Bromide Tablets are contraindicated in mechanical
intestinal or urinary obstruction, and
particular caution should be used in its administration to patients
with bronchial asthma. Care should be
observed in the use of atropine for counteracting side effects, as
discussed below.
WARNINGS
Although failure of patients to show clinical improvement may reflect
underdosage, it can also be
indicative of overdosage. As is true of all cholinergic drugs,
overdosage of Pyridostigmine Bromide
Tablets may result in cholinergic crisis, a state characterized by
increasing muscle weakness which,
through involvement of the muscles of respiration, may lead to death.
Myasthenic crisis due to an
increase in the severity of the disease is also accompanied by extreme
muscle weakness, and thus may
be difficult to distinguish from cholinergic crisis on a symptomatic
basis. Such differentiation is
extremely important, since increases in doses of Pyridostigmine
Bromide Tablets or other drugs of this